Head-to-head · WeighScore
No BS RX vs WellMedr
By GLP-1 ScorecardUpdated
Score comparison
No BS RX has the higher recorded score — 82.8/100 to 63.2/100.
No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.
Before you choose
Before comparing the headline prices, the No BS RX review and the WellMedr review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, No BS RX vs Wellorithm and NuuVim vs WellMedr compare each of them with another graded program, and the list of alternatives to No BS RX ranks the programs closest to No BS RX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | No BS RX | WellMedr |
|---|---|---|
| WeighScore | 82.8/100 | 63.2/100 |
| Grade | B− | C |
| Site position | #23 | #214 |
| Semaglutide | $149/mo advertised for standard compounded injection; low-dose priced separately | Advertised from $41/month under a sale banner on November 11 ($49 in October); selected upfront total, plan term and renewal amount need confirmation |
| Tirzepatide | $225/mo advertised for standard compounded injection; low-dose priced separately | Advertised from $71/month under a sale banner on November 11 ($89 in October); selected upfront total, plan term and renewal amount need confirmation |
| Coverage | Confirm program availability for your state | General service page lists all 50 states, DC, Puerto Rico and Guam; exact medication, clinical eligibility and pharmacy fulfillment remain conditional |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Strengths
- Displays monthly and prepaid amounts by program
- Advertises consultation, medication, shipping and messaging in the compounded plans
- Lists branded Ozempic and Zepbound separately
What to consider
- The $115 headline applies to low-dose programs
- Plans renew automatically at the then-current rate
- Cancellation generally stops future billing without refunding the current period
Strengths
- Publishes separate descriptions of 21-day billing and fully prepaid three-, six- and twelve-month plans
- The refund policy provides detailed renewal and unused-prepayment rules, although important provisions conflict with the Terms
- Current documents name possible pharmacy partners, including Logos, Emerald and Center City; the assigned facility still needs confirmation
- The safety page distinguishes compounded preparations from FDA-approved products rather than treating shared ingredients as proof of equivalence
What to consider
- Starting $41 and $71 sale advertisements do not establish the total due today, renewal amount or usable prescription supply; confirm whether membership and medication are separate charges
- Four-week shipping is not the billing calendar; the separately described 21-day plan can generate more frequent charges
- The refund policy accepts cancellation before a charge is submitted, while the Terms require two days’ notice and allow early renewal processing
- Unused-prepayment allocation in the refund policy conflicts with discretionary partial refunds, medication-plan cancellation windows and a nonrefundable first membership month in the Terms; no legal priority is established
- The ninety-day results-refund promise conflicts with policy language denying a results guarantee; clarify the selected written agreement
- The current directory does not establish an available oral or microdose GLP-1 purchase; the homepage labels microdose Coming soon
- Current documents do not identify the assigned clinical practice, clinician, dispenser or physical compounder; general service coverage does not guarantee every preparation
Featured provider
WellMedr
Factor scores not reassessed.WellMedr scores 63.2/100 (C). Advertises low starting prices, but its 21-day and prepaid payment choices come with conflicting cancellation and refund terms; confirm the full bill and selected written agreement before committing.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.